Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ROS1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ROS1 mutation	Non Small Cell Lung Cancer	ROS1 mutation	Non Small Cell Lung Cancer	VEGFR-2 inhibitor Sensitive: C3 – Early Trials VEGFR-2 inhibitor Sensitive : C3	VEGFR-2 inhibitor Sensitive: C3 – Early Trials VEGFR-2 inhibitor Sensitive : C3
ROS1 mutation	Non Small Cell Lung Cancer	ROS1 mutation	Non Small Cell Lung Cancer	entrectinib Resistant: C3 – Early Trials entrectinib Resistant : C3	entrectinib Resistant: C3 – Early Trials entrectinib Resistant : C3
ROS1 mutation	Solid Tumor	ROS1 mutation	Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ROS1 mutation	Non Small Cell Lung Cancer	ROS1 mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ROS1 mutation	Head and Neck Cancer	ROS1 mutation	Head and Neck Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
ROS1 mutation	Non Small Cell Lung Cancer	ROS1 mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ROS1 mutation	Non Small Cell Lung Cancer	ROS1 mutation	Non Small Cell Lung Cancer	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D